Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study

被引：0
|
作者：
Wang, Jiabei
Peng, Tao
Liu, Chang
Zhang, Ling
Zhu, Guangzhi
Zhang, Xiaogang
Wang, Xiaoqian
Liu, Lianxin
机构：
[1] USTC, Affiliated Hosp 1, Hefei, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16239
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma
    Hasanov, Merve
    Milton, Denai R.
    Sharfman, William H.
    Taback, Bret
    Cranmer, Lee D.
    Daniels, Gregory A.
    Flaherty, Lawrence
    Hallmeyer, Sigrun
    Milhem, Mohammed
    Feun, Lynn
    Hauke, Ralph
    Doolittle, Gary
    Gregory, Nancy
    Patel, Sapna
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [32] Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study
    Wang, Lijun
    Wang, Hongwei
    Cui, Yong
    Jin, Kemin
    Liu, Wei
    Wang, Kun
    Xing, Baocai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO
    Rexer, H.
    Retz, M.
    Albers, P.
    UROLOGE, 2016, 55 (11): : 1491 - 1493
  • [34] A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE II STUDY TO COMPARE BEVACIZUMAB PLUS SORAFENIB VERSUS SORAFENIB FOR THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (NCT02330783)
    Guo, Jun
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Siming
    Mao, Lili
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Kong, Yan
    Dai, Jie
    Zhou, F. J.
    Ye, D. W.
    He, Z. S.
    ANTICANCER RESEARCH, 2015, 35 (07) : 4299 - 4300
  • [35] A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783)
    Guo, Jun
    Sheng, Xi Nan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Si Ming
    Mao, Li Li
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Zhou, Fang-Jian
    Ye, Dingwei
    He, Zhisong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] A Randomized, Multi-center, Phase IV Open-label Study to Evaluate and Compare the Effect of Carvedilol versus Propranolol on Reduction in Portal Pressure in Patients with Cirrhosis: an Interim Analysis
    Sohn, Joo Hyun
    Kim, Tae Yeob
    Um, Soon Ho
    Seo, Yeon Seok
    Baik, Soon Koo
    Kim, Moon Young
    Jang, Jae Young
    Jeong, Soung Won
    Kim, Young Seok
    Kim, Sang Gyune
    Kim, Dong Joon
    Suk, Ki Tae
    Jeong, Woo Kyoung
    HEPATOLOGY, 2013, 58 : 990A - 990A
  • [37] Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery-A single arm, multi-center, phase II clinical trial
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 588 - 588
  • [38] Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery: A single arm, multi-center, phase II clinical trial.
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 513 - 513
  • [39] A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
    Hasanov, Elshad
    Hammers, Hans J.
    George, Daniel J.
    Rini, Brian I.
    Beckermann, Katy
    Palmer, Joshua David
    Mortazavi, Amir
    Brooks, Roserika
    Solley, Travis
    Wood, Lauren Michelle
    Haas, Naomi B.
    McDermott, David F.
    Vaishampayan, Ulka N.
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS497 - TPS497
  • [40] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
12345